本帖最后由 老马 于 2012-1-13 21:20 编辑
$ {- Q7 E3 l" m' k6 B
5 ~4 a6 |9 n$ o2 o6 E爱必妥和阿瓦斯丁的比较
% m6 g% w, o9 V+ C( l
3 M8 h$ |: ?- }! d" O; @
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/, `/ y0 V% l0 U0 i! Z/ ^
* F; [: b" d/ ?- a7 ? N$ |2 ^& q
+ X8 I0 l% h& @# Z$ Z8 W0 v6 A2 _/ @http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* j& d2 N7 `1 t% Z# y# Y1 Q
==================================================) k z I. G, W. S4 x1 A8 N: ]. f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 U; T! t3 W2 `: IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# z/ ?3 e6 H3 i; e& R2 `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ [' E5 V9 M) ~& s, i
|